Home › Therapeutic areas › Oncology › Prostate Cancer
Prostate Cancer (22 companies)
Companies with an active program in Prostate Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | $172M | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $26.0M | 8 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $910M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.12B | 6 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | $1.6M | 8 |
| ARVN | Arvinas | NeurologyOncology Rare | 2 | Approved | $447M | 10 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $30.7M | 8 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $424M | 4 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $74.0M | 5 |
| EIKN | Eikon Therapeutics | Oncology | 3 | Phase 2 | $279M | 13 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| JANX | Janux Therapeutics | Oncology | 3 | Phase 1 | $655M | 4 |
| KAPA | Kairos Pharma | Oncology | 2 | Phase 2 | $1.9M | 12 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| OLMA | Olema Pharmaceuticals | Oncology | 1 | Phase 3 | $633M | 3 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $831M | 5 |
| TLX | Telix Pharmaceuticals | Oncology | 9 | Approved | $3.01B | 25 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | $1.58B | 6 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.59B | 28 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $1.78B | 12 |
No companies match.